Peroxisome proliferator-activated receptor-γ suppresses CYP11B2 expression and aldosterone production

Journal of Molecular Endocrinology

Volumn 46, Issue 1, 2011, Pages 37-49

  Uruno, Akira ^a   Matsuda, Ken ^a   Noguchi, Naoya ^a   Yoshikawa, Takeo ^a   Kudo, Masataka ^a   Satoh, Fumitoshi ^a   Rainey, William E ^b   Hui, Xiao Gang ^a   Akahira, Jun Ichi ^a   Nakamura, Yasuhiro ^a   Sasano, Hironobu ^a   Okamoto, Hiroshi ^a   Ito, Sadayoshi ^a   Sugawara, Akira ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DERIVATIVE; ALDOSTERONE SYNTHASE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE I; IONOMYCIN; N6 2' O DIBUTYLADENOSINE 3' 5' CYCLIC MONOPHOSPHATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; UNCLASSIFIED DRUG;

ADRENAL GLAND; ALDOSTERONE RELEASE; ARTICLE; GENE EXPRESSION; GENE MUTATION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; ZONA GLOMERULOSA;

ADRENAL CORTEX; ALDOSTERONE; ALDOSTERONE SYNTHASE; BENZOPHENONES; BENZYLAMINES; BLOTTING, WESTERN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1; CELL LINE; GENE EXPRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IONOMYCIN; MUTATION; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; TYROSINE; ZONA GLOMERULOSA;

EID: 79551711715     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-10-0088     Document Type: Article

References (39)

1. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ et al. 1999 Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 880-883. (doi:10.1038/47254)
2. Bassett MH, Zhang Y, White PC & Rainey WE 2000 Regulation of human CYP11B2 and CYP11B1: comparing the role of the common CRE/Ad1 element. Endocrine Research 26 941-951. (doi:10.3109/07435800009048620)
3. Bassett MH, Zhang Y, Clyne C, White PC & Rainey WE 2002 Differential regulation of aldosterone synthase and 11β-hydroxylase transcription by steroidogenic factor-1. Journal of Molecular Endocrinology 28 125-135. (doi:10.1677/jme.0.0280125)
4. Bassett MH, Suzuki T, Sasano H, White PC & Rainey WE 2004 The orphan nuclear receptors NURR1 and NGFIB regulate adrenal aldosterone production. Molecular Endocrinology 18 279-290. (doi:10.1210/me.2003-0005)
5. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M & Beuschlein F 2005 Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation. Journal of Clinical Endocrinology and Metabolism 90 3886-3896. (doi:10.1210/jc.2004-1267)
6. Clyne CD, Zhang Y, Slutsker L, Mathis JM, White PC & Rainey WE 1997 Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Molecular Endocrinology 11 638-649. (doi:10.1210/me.11.5.638)
7. Condon JC, Pezzi V, Drummond BM, Yin S & Rainey WE 2002 Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase. Endocrinology 143 3651-3657. (doi:10.1210/en.2001-211359)
8. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF & Schiffrin EL 2002 Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 105 2296-2302. (doi:10.1161/01.CIR.0000016049.86468.23)
9. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD et al. 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 1279-1289. (doi:10.1016/S0140-6736(05)67528-9)
10. Ferruzzi P, Kliewer P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, Fiorelli G, Serio M & Mannelli M 2005 Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. Journal of Clinical Endocrinology and Metabolism 90 1332-1339. (doi:10.1210/jc.2004-0978)
11. Freedman BD, Lee EJ, Park Y & Jameson JL 2005 A dominant negative peroxisome proliferator-activated receptor-γ knock-in mouse exhibits features of the metabolic syndrome. Journal of Biological Chemistry 280 17118-17125. (doi:10.1074/jbc.M407539200)
12. Gearing KL, Gottlicher M, Teboul M, Widmark E & Gustafsson JA 1993 Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. PNAS 90 1440-1444. (doi:10.1073/pnas.90.4.1440)
13. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y & Breyer MD 2005 Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nature Medicine 11 861-866. (doi:10.1038/nm1278)
14. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW et al. 2000 A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. Journal of Biological Chemistry 275 5754-5759. (doi:10.1074/jbc.275.8.5754)
15. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM & Sigmund CD 2008 Interference with PPARγ function in smooth muscle causes vascular dysfunction and hypertension. Cell Metabolism 7 215-226. (doi:10.1016/j.cmet.2007.12.008)
16. Harte A, McTernan P, Chetty R, Coppack S, Katz J, Smith S & Kumar S 2005 Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 111 1954-1961. (doi:10.1161/01.CIR.0000161954.17870.5D)
17. Heikkinen S, Auwerx J & Argmann CA 2007 PPARγ in human and mouse physiology. Biochimica et Biophysica Acta 1771 999-1013. (doi:10.1016/j.bbalip.2007.03.006)
18. IJpenberg A, Jeannin E, Wahli W & Desvergne B 1997 Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. Journal of Biological Chemistry 272 20108-20117. (doi:10.1074/jbc.272.32.20108)
19. Ikeda Y, Sugawara A, Taniyama Y, Uruno A, Igarashi K, Arima S, Ito S & Takeuchi K 2000 Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor γ in macrophages via an interaction with NRF2. Journal of Biological Chemistry 275 33142-33150. (doi:10.1074/jbc.M002319200)
20. Jiang C, Ting AT & Seed B 1998 PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 82-86. (doi:10.1038/35154)
21. Kempna P, Hofer G, Mullis PE & Fluck CE 2007 Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Molecular Pharmacology 71 787-798. (doi:10.1124/mol.106.028902)
22. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K & Evans RM 1994 Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. PNAS 91 7355-7359. (doi:10.1073/pnas.91.15.7355)
23. Park Y, Freedman BD, Lee EJ, Park S & Jameson JL 2003 A dominant negative PPARγ mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia 46 365-377. (doi:10.1007/s00125-003- 1177-6)
24. 2+-regulated expression of aldosterone synthase is mediated by calmodulin and calmodulin-dependent protein kinases. Endocrinology 138 835-838. (doi:10.1210/en.138.2.835)
25. Rainey WE, Saner K & Schimmer BP 2004 Adrenocortical cell lines. Molecular and Cellular Endocrinology 228 23-38. (doi:10.1016/j.mce.2003.12.020)
26. Ricote M, Li AC, Willson TM, Kelly CJ & Glass CK 1998 The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 79-82. (doi:10.1038/34178)
27. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH & Adler GK 2000 Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 3871-3878. (doi:10.1210/en.141.10.3871)
28. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J & McMahon E 2002 Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143 4828-4836. (doi:10.1210/en.2002-220120)
29. Ryan MJ, Didion SP, Mathur S, Faraci FM & Sigmund CD 2004 PPAR(γ) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 661-666. (doi:10.1161/01.HYP.0000116303.71408.c2)
30. Sahar S, Reddy MA, Wong C, Meng L, Wang M & Natarajan R 2007 Cooperation of SRC-1 and p300 with NF-κB and CREB in angiotensin II-induced IL-6 expression in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 27 1528-1534. (doi:10.1161/ATVBAHA.107.145862)
31. Sato K, Sugawara A, Kudo M, Uruno A, Ito S & Takeuchi K 2004 Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertension Research 27 417-425. (doi:10.1291/hypres.27.417)
32. Sugawara A, Takeuchi K, Uruno A, Ikeda Y, Arima S, Kudo M, Sato K, Taniyama Y & Ito S 2001 Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Endocrinology 142 3125-3134. (doi:10.1210/en.142.7.3125)
33. Sugawara A, Uruno A, Kudo M, Ikeda Y, Sato K, Taniyama Y, Ito S & Takeuchi K 2002 Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-γ via an interaction with Sp1 in vascular smooth muscle cells. Journal of Biological Chemistry 277 9676-9683. (doi:10.1074/jbc.M104560200)
34. 2+/ calmodulin-dependent protein kinases type I, II, and IV. Journal of Biological Chemistry 271 3066-3073. (doi:10.1074/jbc.271.6.3066)
35. Todorov VT, Desch M, Schmitt-Nilson N, Todorova A & Kurtz A 2007 Peroxisome proliferator-activated receptor-γ is involved in the control of renin gene expression. Hypertension 50 939-944. (doi:10.1161/HYPERTENSIONAHA. 107.092817)
36. Uruno A, Sugawara A, Kanatsuka H, Arima S, Taniyama Y, Kudo M, Takeuchi K & Ito S 2004 Hepatocyte growth factor stimulates nitric oxide production through endothelial nitric oxide synthase activation by the phosphoinositide 3-kinase/Akt pathway and possibly by mitogen-activated protein kinase kinase in vascular endothelial cells. Hypertension Research 27 887-895. (doi:10.1291/hypres.27.887)
37. Uruno A, Sugawara A, Kanatsuka H, Kagechika H, Saito A, Sato K, Kudo M, Takeuchi K & Ito S 2005 Upregulation of nitric oxide production in vascular endothelial cells by all-trans retinoic acid through the phosphoinositide 3-kinase/Akt pathway. Circulation 112 727-736. (doi:10.1161/CIRCULATIONAHA.104. 500959)
38. Uruno A, Sugawara A, Kudo M, Satoh F, Saito A & Ito S 2008 Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: involvement of p38 mitogen-activated protein kinase. Hypertension Research 31 2085-2096. (doi:10.1291/hypres.31.2085)
39. Walker AB, Chattington PD, Buckingham RE & Williams G 1999 The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48 1448-1453. (doi:10.2337/diabetes.48.7.1448)